{
    "root": "2f9d80c1-3d8f-b949-e063-6294a90af1cc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amlodipine and Benazepril Hydrochloride",
    "value": "20250305",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 5",
            "code": "I753WB2F1M"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMLODIPINE BESYLATE",
            "code": "864V2Q084H"
        },
        {
            "name": "BENAZEPRIL HYDROCHLORIDE",
            "code": "N1SN99T69T"
        }
    ],
    "indications": "amlodipine benazepril hydrochloride capsules combination capsule amlodipine , dihydropyridine calcium channel blocker ( dhp ccb ) benazepril , angiotensin-converting enzyme ( ace ) inhibitor . amlodipine benazepril hydrochloride capsules indicated treatment hypertension patients adequately controlled monotherapy either agent . ( 1 )",
    "contraindications": "usual starting dose 2.5 mg/10 mg. ( 2.1 ) may used add-on therapy patients adequately controlled either dihydropyridine calcium channel blocker ace inhibitor ( 2.2 ) patients experience edema amlodipine may switched amlodipine benazepril hydrochloride capsules containing lower dose amlodipine . ( 2.1 )",
    "warningsAndPrecautions": "amlodipine benazepril hydrochloride capsules usp , 10 mg/20 mg white pale yellow colored powder filled empty hard gelatin capsule shells , size \u201c 0 \u201d purple cap purple body imprinted \u2018 j \u2019 purple cap \u2018 02 \u2019 purple body black edible ink . ndc : 70518-2140-00 packaging : 90 1 bottle plastic storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight container ( usp ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "coadminister aliskiren angiotensin receptor blockers ( arbs ) , angiotensin-converting enzyme ( ace ) inhibitors , including amlodipine benazepril hydrochloride capsules patients diabetes . amlodipine benazepril hydrochloride capsules contraindicated patients history angioedema , without previous ace inhibitor treatment , patients hypersensitive benazepril , ace inhibitor , amlodipine , excipients amlodipine benazepril hydrochloride capsules . amlodipine benazepril hydrochloride capsules contraindicated combination neprilysin inhibitor ( e.g . , sacubitril ) . administer amlodipine benazepril hydrochloride capsules within 36 hours switching neprilysin inhibitor , e.g . , sacubitril/valsartan [ ( 5.1 ) ] .",
    "indications_original": "Amlodipine and benazepril hydrochloride capsules\u00a0are a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin-converting enzyme (ACE) inhibitor. Amlodipine and benazepril hydrochloride capsules\u00a0are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. (1)",
    "contraindications_original": "Usual starting dose is 2.5 mg/10 mg. ( 2.1 ) May be used as add-on therapy for patients not adequately controlled with either a dihydropyridine calcium channel blocker or an ACE inhibitor ( 2.2 ) Patients who experience edema with amlodipine may be switched to amlodipine and benazepril hydrochloride capsules containing a lower dose of amlodipine. ( 2.1 )",
    "warningsAndPrecautions_original": "Amlodipine and Benazepril Hydrochloride Capsules USP, 10 mg/20 mg\u00a0are white to pale yellow colored powder filled in empty hard gelatin capsule shells, size \u201c0\u201d of purple cap and purple body imprinted with \u2018J\u2019 on purple cap and \u201802\u2019 on purple body with black edible ink.\n                  \n                  NDC: 70518-2140-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in tight container (USP).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Do not coadminister aliskiren\u00a0with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes.\n                     Amlodipine and benazepril hydrochloride capsules\u00a0 are contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules.\n                     Amlodipine and benazepril hydrochloride capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan\n  \n   [see\n                        \n                           \n                              \n                                 Warnings and Precautions (5.1)\n                              ]."
}